New methods of identification have led to an ever-increasing number of unusual pathogens causing infection in the immunocompromised host. Reports of antimicrobial-resistant organisms in this group of patients are also increasing, with the result that new treatments must be sought urgently. New agents and new strategies for the development of antimicrobial agents are critical for future progress in the treatment of resistant organisms.